Trial Information

Official Title: A Multicenter, Open-label Extension, Multiple-dose, Parallel Group Study to Investigate the Long-term Safety and Tolerability of AAB-003 (PF-05236812) Administered Intravenously in Subjects With Mild to Moderate Alzheimer's Disease Previously Treated With AAB-003 or Placebo in Protocol B2601001

Summary

This is a study to evaluate the safety and tolerability of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease. Patients who complete study B2601001 may participate in this trial and receive AAB-003 (PF-05236812). Each patient's participation will last approximately 52 weeks.

Phase: Phase 1

Sponsor: Pfizer

Overall Contacts:

Pfizer CT.gov Call Center
1-800-718-1021